These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16019538)

  • 1. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.
    Imamura T; Yokosuka O; Chiba T; Kanda T; Kojima H; Fukai K; Imazeki F; Nishimura M; Saito Y; Saisho H
    Leuk Lymphoma; 2005 Jun; 46(6):915-7. PubMed ID: 16019538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region.
    Kitano K; Kobayashi H; Hanamura M; Furuta K; Ueno M; Rokuhara A; Tanaka E; Umemura T; Kiyosawa K
    Eur J Haematol; 2006 Sep; 77(3):255-8. PubMed ID: 16923112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation.
    Hashino S; Nozawa A; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Hige S; Asaka M
    Bone Marrow Transplant; 2002 Feb; 29(4):361-3. PubMed ID: 11896435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation.
    Picardi M; Selleri C; De Rosa G; Raiola A; Pezzullo L; Rotoli B
    Bone Marrow Transplant; 1998 Jun; 21(12):1267-9. PubMed ID: 9674862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful allogeneic bone marrow transplantation from an HBV-positive donor into an HBV-positive recipient using lamivudine.
    Hashino S; Takahata M; Nozawa A; Izumiyama K; Chiba K; Suzuki S; Hige S; Asaka M
    Bone Marrow Transplant; 2002 Feb; 29(3):269-71. PubMed ID: 11859401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation.
    Schubert A; Michel D; Mertens T
    BMC Infect Dis; 2013 May; 13():223. PubMed ID: 23679074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Yaşar DG; Suyanı E; Özenirler S; Sucak GT
    Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of lamivudine in the treatment of reactivation of chronic hepatitis B virus infection in patients on immunosuppressive therapy].
    Popović N; Stojković-Švirtlih N; Simonović-Babić J; Boričić I; Tomanović N; Mitrović N; Delić D
    Srp Arh Celok Lek; 2011; 139(11-12):824-7. PubMed ID: 22338485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor.
    Sobhonslidsuk A; Ungkanont A
    World J Gastroenterol; 2007 Feb; 13(7):1138-40. PubMed ID: 17373754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B immunoglobulin in combination with lamivudine for prevention of hepatitis B virus reactivation in children undergoing bone marrow transplantation.
    Tavil B; Kuşkonmaz B; Kasem M; Demir H; Cetin M; Uçkan D
    Pediatr Transplant; 2006 Dec; 10(8):966-9. PubMed ID: 17096768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.